Event date: 11 – 12 May 2022
It’s been a dynamic period for Australia’s biotech sector. Since the last Bioshares Biotech Summit, there have been 28 new biotech listings on the ASX and in just the last two years, $3.4 billion has been raised (excluding CSL’s $6.3 billion raise late last year) which is almost double the amount raised over the previous two years.
So it’s time to meet up in person (!), share experiences, and get updated on these biotech investment opportunities. A new date for 16th Bioshares Biotech Summit has been set, 11-12 May 2022, at the Albury Entertainment Centre. Ideally positioned between Melbourne, Sydney and Canberra, Albury-Wodonga is a thriving cultural and wine destination. Albury has been selected because of the ease of access from most capital cities via road or by air with direct flights from Melbourne, Sydney and Brisbane.
With function uncertainties from the current coronavirus pandemic, attendees are recommended to register now to secure a spot, with payment to be made two weeks prior to the event. Those attendees who registered last year will have their registration automatically rolled over to this year’s Summit.
Whilst this event has been deferred several times, we are committed to ensuring the Summit continues on the biotech calendar, in person, and once again are very appreciative of the event/sector sponsors ñ biotech insurance group Avatar Brokers, IP firm FB Rice and Telix Pharmaceuticals.
The Summit is an ideal event for fund managers, stockbrokers and investment bankers active in the sector as well as retail investors who have a committed interest in biotech stocks or are looking to build their knowledge and networks in this space. The Cocktail Reception will be held at The Albury Club, and the closing dinner will be at the All Saints Estate winery.
This year’s event will be capped at 200 people from the biotech industry and investment markets. The Bioshares Biotech Summit has established a reputation as a high-level meeting with leading companies in the sector delving deep into their business strategies, challenges and opportunities ahead. It has also become an excellent, turf-neutral networking event where investors can gain intimate access with biotech CEOs and management.
An obvious discussion point for this year’s Summit is how the coronavirus pandemic is impacting biotech businesses and how are companies adapting to the challenging environment. What are the new opportunities and what are the current challenges for breaking into new markets and conducting trials? Are Australian biotechs too US-focused and how are other markets being explored? Australian biotechs have been busy buying other assets and companies; will we start to see local companies getting acquired soon? And we will hear from some of the recently listed biotechs.
We hope you can join us for the 16th Bioshares Biotech Summit in Albury!
Mark Pachacz & Paris Brooke